DJIA 17,882.53 -253.19 -1.40%
NASDAQ 4,935.22 -47.59 -0.96%
S&P 500 2,074.47 -26.57 -1.26%
market minute promo

Epizyme (NASDAQ: EPZM)

22.95 -1.46 (-5.98%)

Quote as of

company name or ticker

Recent Quotes

EPZM $22.95 -5.98%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $24.28
Previous Close $24.41
Daily Range $22.64 - $24.28
52-Week Range $16.51 - $40.98
Market Cap $784.0M
P/E Ratio 610.25
Dividend (Yield) $0.00 (0.0%)
Volume 249,578
Average Daily Volume 208,343
Current FY EPS -$1.76



Epizyme (EPZM) Description

Epizyme Inc is a clinical stage biopharmaceutical company that discovers develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers. Website:

News & Commentary

5 Predictions for Biotechnology Stocks in 2015

Celgene Corp, Alkermes, GW Pharmaceuticals, Gilead Sciences, and Hospira should all be on investors radar in 2015.

Will Epizyme (EPZM) Miss Estimates This Earnings Season? - Analyst Blog

Excitement For Epizyme

Primecap Exceeds 5% Threshold In Shutterfly, 3 Other Companies

Epizyme: The Ugly Duckling Of The 2014 Biotech Rally?

Commit To Purchase Epizyme At $15, Earn 11.5% Annualized Using Options

Epizyme: Shares Oversold On Mixed Data From Early Studies

RSI Alert: Epizyme (EPZM) Now Oversold

3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't

Gilead Sciences, Celgene, and Biogen all have rock-solid financials, but none are likely to pay a dividend anytime soon.

Epizyme Gains on Positive Phase I Data on EPZ-6438 - Analyst Blog

See More EPZM News...